lebrikizumab vs tralokinumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-13 · full Atopic Dermatitis pipeline
lebrikizumab · Ebglyss
Marketed by Eli Lilly and partners
NCT04146363 · Phase 3 · completed
The randomized, quadruple-masked, placebo-controlled trial enrolled 424 participants and evaluated clinical skin outcomes as its two primary endpoints. At Week 16, both endpoints were met: IGA 0/1 response was 43.1% with lebrikizumab versus 12.7% with placebo (p<0.000001), and EASI-75 response was 58.8% versus 16.2% (p<0.000001).
Next expected readout: April 2027 · NCT06526182 (registry estimate)
Reported efficacy
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16; Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) (met)
Result source: NCT04178967
tralokinumab · Adbry
Marketed by LEO Pharma and partners
NCT05958407 · Phase 3 · completed
The 235 participants were randomized 2:1 to tralokinumab or placebo and the initial 16-week comparison was double-blinded. The primary clinical endpoint—an Investigator’s Global Assessment score of 0 or 1 at Week 16—was met, occurring in 40.0% of the tralokinumab group versus 10.6% of the placebo group (p<.001).
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) (met)
Result source: NCT05958407
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | lebrikizumab | tralokinumab |
|---|---|---|
| EASI-75 | 51.2% vs 13.4%+37.8 vs placeboNCT0476031410 other results
| 25% vs 12.7%+12.3 vs placeboNCT031316488 other results
|
| IGA 0/1 with 2-point improvement | 33.4% vs 6.1%+27.3 vs placeboNCT047603145 other results
| 11.6% vs 11.8%−0.2 vs placeboNCT023471762 other results
|
| EASI-90 | 34.3% vs 9.8%+24.5 vs placeboNCT0476031411 other results
| 14.5% vs 4.1%+10.4 vs placeboNCT031316485 other results
|
| EASI, % change | -64.2% vs -25.3%−39 vs placeboNCT047603147 other results
| -77.8% vs -73.5%−4.3 vs placeboNCT04587453 |
EASI-75
- lebrikizumab
- 51.2% vs 13.4%+37.8 vs placeboNCT04760314
10 other results
- 58.8% vs 16.2% NCT04146363
- 52.1% vs 18.1% NCT04178967
- 47.2% vs 13.4% NCT04760314
- 69.5% vs 42.2% NCT04250337
- 58% vs 32.7% NCT04626297
- 84.7% vs 72% NCT04178967
- 77.4% vs 72% NCT04178967
- 60.6% vs 24.3% NCT03443024
- 56.1% vs 24.3% NCT03443024
- 43.3% vs 24.3% NCT03443024
- tralokinumab
- 25% vs 12.7%+12.3 vs placeboNCT03131648
8 other results
- 33.2% vs 11.4% NCT03160885
- 27.8% vs 6.4% NCT03526861
- 28.6% vs 6.4% NCT03526861
- 56% vs 35.7% NCT03363854
- 71.7% vs 56.6% NCT04587453
- 64.2% vs 50.5% NCT03761537
- 68.8% vs 55.3% NCT03761537
- 49.1% vs 36.1% NCT03562377
IGA 0/1 with 2-point improvement
- lebrikizumab
- 33.4% vs 6.1%+27.3 vs placeboNCT04760314
5 other results
- 29.1% vs 6.1% NCT04760314
- 41.2% vs 22.1% NCT04250337
- 44.6% vs 15.3% NCT03443024
- 33.7% vs 15.3% NCT03443024
- 26.6% vs 15.3% NCT03443024
- tralokinumab
- 11.6% vs 11.8%−0.2 vs placeboNCT02347176
2 other results
- 19.5% vs 11.8% NCT02347176
- 26.7% vs 11.8% NCT02347176
EASI-90
- lebrikizumab
- 34.3% vs 9.8%+24.5 vs placeboNCT04760314
11 other results
- 39.2% vs 18.9% NCT04626297
- 38.3% vs 9% NCT04146363
- 30.7% vs 9.5% NCT04178967
- 41.2% vs 21.7% NCT04250337
- 12.4% vs 1.6% NCT04146363
- 6.3% vs 1.5% NCT04178967
- 28.4% vs 9.8% NCT04760314
- 10.7% vs 7.2% NCT04250337
- 44% vs 11.4% NCT03443024
- 36.1% vs 11.4% NCT03443024
- 26.1% vs 11.4% NCT03443024
- tralokinumab
- 14.5% vs 4.1%+10.4 vs placeboNCT03131648
5 other results
- 18.3% vs 5.5% NCT03160885
- 17.5% vs 4.3% NCT03526861
- 19.4% vs 4.3% NCT03526861
- 32.9% vs 21.4% NCT03363854
- 45.3% vs 30.2% NCT04587453
EASI, % change
- lebrikizumab
- -64.2% vs -25.3%−39 vs placeboNCT04760314
7 other results
- -64.3% vs -26.0% NCT04146363
- -61.5% vs -28.0% NCT04178967
- -59.7% vs -25.3% NCT04760314
- -76.8% vs -53.1% NCT04250337
- -72.1% vs -41.1% NCT03443024
- -69.2% vs -41.1% NCT03443024
- -62.3% vs -41.1% NCT03443024
- tralokinumab
- -77.8% vs -73.5%−4.3 vs placeboNCT04587453
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. lebrikizumab: 14 of 14 rows · tralokinumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | lebrikizumab Rows use multiple source trials | tralokinumab Rows use multiple source trials |
|---|---|---|
| CDLQI absolute change · score | -8 vs -1 placebo score @ 16wkQ2Wa,b NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 other source trials-7.6 vs -3.4 placebo score @ 16wkQ2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -9.33 vs -4.71 placebo score @ 16wk NCT04250337 · Phase 3 · combination | -6.7 vs -4.1 placebo score @ 16wk300 mg Q2Wc,a,b NCT03526861 · Phase 3 show 1 more dose-6.1 vs -4.1 placebo score @ 16wk150 mg Q2W NCT03526861 · Phase 3 |
| DLQI absolute change · score | -8.7 vs -2.9 placebo score @ 16wkQ2Wa,b NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 other source trials-7.3 vs -2.4 placebo score @ 16wkQ2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -9.79 vs -6.46 placebo score @ 16wk NCT04250337 · Phase 3 · combination | -7.1 vs -5 placebo score @ 16wk300 mg Q2Wa,b NCT03131648 · Phase 3 4 other source trials-8.8 vs -4.9 placebo score @ 16wk300 mg Q2W NCT03160885 · Phase 3 -11.7 vs -8.8 placebo score @ 16wkQ2W+TCS NCT03363854 · Phase 3 · combination -10 vs -8.8 placebo score @ 16wk NCT04587453 · Phase 3 · registry result, not featured evidence · combination -11.2 vs -9.6 placebo score @ 16wk NCT03761537 · Phase 3 · registry result, not featured evidence · combination |
| DLQI ≥4 responder rate · % of participants | 77.4% (n=105) vs 58.7% (n=48) placebo @ 16wka,b NCT04250337 · Phase 3 · combination | 44.6% (n=578) vs 31.6% (n=190) placebo @ 16wk*300 mg Q2Wa,b NCT03131648 · Phase 3 · converted to % from 258 Participants as posted |
| EASI-50 responder rate · % of participants | 81% (n=75) vs 45.8% (n=52) placebo @ 16wk250 mg Q2Wc,d,a,b NCT03443024 · Phase 2 · registry result, not featured evidence show 2 more doses77% (n=80) vs 45.8% (n=52) placebo @ 16wk250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence 66.4% (n=73) vs 45.8% (n=52) placebo @ 16wk125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence | 41.6% (n=601) vs 21.3% (n=197) placebo @ 16wk*300 mg Q2Wd,a,b NCT03131648 · Phase 3 · converted to % from 250 Participants as posted 5 other source trials49.9% (n=591) vs 20.4% (n=201) placebo @ 16wk*300 mg Q2W NCT03160885 · Phase 3 · converted to % from 295 Participants as posted 79.4% (n=252) vs 57.9% (n=126) placebo @ 16wk*Q2W+TCS NCT03363854 · Phase 3 · combination · converted to % from 200 Participants as posted 45.9% (n=98) vs 13.8% (n=94) placebo @ 16wk*150 mg Q2W NCT03526861 · Phase 3 · converted to % from 45 Participants as posted 51.5% (n=97) vs 13.8% (n=94) placebo @ 16wk*300 mg Q2W NCT03526861 · Phase 3 · converted to % from 50 Participants as posted 84.9% (n=53) vs 79.2% (n=53) placebo @ 16wk* NCT04587453 · Phase 3 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted |
| EASI-75 responder rate · % of participants No placebo or comparator arm | 81.9% (n=206) @ 52wk250 mga,b NCT04250350 · Phase 3 · registry result, not featured evidence | 53.8% (n=13) @ 52wk*300 mg Q4Wc,a,b NCT03526861 · Phase 3 · converted to % from 7 Participants as posted show 3 more doses44.4% (n=9) @ 52wk*300 mg Q2W NCT03526861 · Phase 3 · converted to % from 4 Participants as posted 63.6% (n=11) @ 52wk*150 mg Q2W NCT03526861 · Phase 3 · converted to % from 7 Participants as posted 50% (n=14) @ 52wk*150 mg Q4W NCT03526861 · Phase 3 · converted to % from 7 Participants as posted |
| EASI-75 Sustained responder rate · % of participants | 79.2% (n=61) vs 61.3% (n=30) placebo @ 52wk250 Q2Wc,a,b NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose79.2% (n=62) vs 61.3% (n=30) placebo @ 52wk250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 49.1% (n=57) vs 33.3% (n=30) placebo @ 52wk*300 mg Q4Wc,a,b NCT03131648 · Phase 3 · converted to % from 28 Participants as posted show 1 more dose59.6% (n=47) vs 33.3% (n=30) placebo @ 52wk*300 mg Q2W NCT03131648 · Phase 3 · converted to % from 28 Participants as posted |
| IGA 0 1 Sustained responder rate · % of participants | 75.8% (n=45) vs 46.5% (n=22) placebo @ 52wk250 Q2Wc,a,b NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose74.2% (n=45) vs 46.5% (n=22) placebo @ 52wk250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 38.9% (n=36) vs 47.4% (n=19) placebo @ 52wk*300 mg Q4Wc,a,b NCT03131648 · Phase 3 · converted to % from 14 Participants as posted show 1 more dose51.3% (n=39) vs 47.4% (n=19) placebo @ 52wk*300 mg Q2W NCT03131648 · Phase 3 · converted to % from 20 Participants as posted |
| IGA 0/1 responder rate · % of participants | 43.1% (n=283) vs 12.7% (n=141) placebo @ 16wkQ2Wc,a,b NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose42.2% (n=246) vs 11.3% (n=123) placebo @ 16wkQ2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 15.8% (n=601) vs 7.1% (n=197) placebo @ 16wk*300 mg Q2Wa,b NCT03131648 · Phase 3 · converted to % from 95 Participants as posted 7 other source trials22.2% (n=591) vs 10.9% (n=201) placebo @ 16wk*300 mg Q2W NCT03160885 · Phase 3 · converted to % from 131 Participants as posted 38.9% (n=252) vs 26.2% (n=126) placebo @ 16wk*Q2W+TCS NCT03363854 · Phase 3 · combination · converted to % from 98 Participants as posted 21.4% (n=98) vs 4.3% (n=94) placebo @ 16wk*150 mg Q2W NCT03526861 · Phase 3 · converted to % from 21 Participants as posted 17.5% (n=97) vs 4.3% (n=94) placebo @ 16wk*300 mg Q2W NCT03526861 · Phase 3 · converted to % from 17 Participants as posted 32.1% (n=53) vs 26.4% (n=53) placebo @ 16wk* NCT04587453 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted 40.9% (n=138) vs 26% (n=137) placebo @ 16wk NCT03761537 · Phase 3 · registry result, not featured evidence · combination 31.1% (n=106) vs 19.4% (n=108) placebo @ 16wk* NCT03562377 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted |
| IGA 0/1 responder rate · % of participants No placebo or comparator arm | 62.6% (n=206) @ 52wk250 mga,b NCT04250350 · Phase 3 · registry result, not featured evidence | 87.5% (n=8) @ 52wk*300 mg Q4Wc,a,b NCT03526861 · Phase 3 · converted to % from 7 Participants as posted show 3 more doses37.5% (n=8) @ 52wk*300 mg Q2W NCT03526861 · Phase 3 · converted to % from 3 Participants as posted 66.7% (n=9) @ 52wk*150 mg Q2W NCT03526861 · Phase 3 · converted to % from 6 Participants as posted 60% (n=10) @ 52wk*150 mg Q4W NCT03526861 · Phase 3 · converted to % from 6 Participants as posted |
| POEM absolute change · score | -11.3 vs -3.9 placebo score @ 16wkQ2Wa,b NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 other source trials-9.5 vs -3.5 placebo score @ 16wkQ2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -10.23 vs -6.24 placebo score @ 16wk NCT04250337 · Phase 3 · combination | -8.4 vs -2.4 placebo score @ 16wk300 mg Q2Wc,a,b NCT03526861 · Phase 3 show 1 more dose-7.8 vs -2.4 placebo score @ 16wk150 mg Q2W NCT03526861 · Phase 3 |
| Dropout rate | —250mg Q2We NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 54 more results—Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250mg Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 7.2% NCT04250337 · Phase 3 · combination 6.5% NCT05990725 · Phase 3 · registry result, not featured evidence —Q4W NCT04392154 · Phase 3 · registry result, not featured evidence —Q8W NCT04392154 · Phase 3 · registry result, not featured evidence 33.3%Q2W NCT04392154 · Phase 3 · registry result, not featured evidence 27%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence 14.4%250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 31.4%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then Q4W NCT05369403 · Phase 3 · registry result, not featured evidence 0%Lebrikizumab Pen NCT06444165 · Phase 3 · registry result, not featured evidence —Lebrikuzimab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 3.6%Double-blind Induction Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence · combination —Open-label Maintenance Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 2.4%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 1.2%250mg Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —250 Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 11%250 mg NCT04626297 · Phase 3 · registry result, not featured evidence 16.5%250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT03443024 · Phase 2 · registry result, not featured evidence 38.8%250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence —125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence | 4.5%Tralokinumabf NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more results—Tralokinumab DB NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Tralokinumab OL NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT03131648 · Phase 3 —Q2W NCT03131648 · Phase 3 —Q4W NCT03131648 · Phase 3 —Q2W + optional TCS NCT03131648 · Phase 3 · combination 5.9%300 mg Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q4W NCT03160885 · Phase 3 —Q2W + Optional TCS NCT03160885 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination 7.1%Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —300 mg Q4W NCT03526861 · Phase 3 6.9%300 mg Q2W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 7%150 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 · combination —150 Q2W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —150 Q2W NCT03526861 · Phase 3 —150 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —300 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 · combination 31.6% NCT03587805 · Phase 3 · registry result, not featured evidence 14%Tralokinumab Subcutaneous Dosing b NCT05194540 · Phase 3 · registry result, not featured evidence —Tralokinumab+TCS Initial Treatment NCT05194540 · Phase 3 · registry result, not featured evidence · combination 0% NCT04587453 · Phase 3 · registry result, not featured evidence · combination —Safety Follow-up Period: Tralokinu NCT03761537 · Phase 3 · registry result, not featured evidence · combination —Treatment Period: Tralokinumab+TCS NCT03761537 · Phase 3 · registry result, not featured evidence · combination 6.5% NCT03562377 · Phase 2 · registry result, not featured evidence 20%Tralokinumab Dose 1 NCT02347176 · Phase 2 · registry result, not featured evidence 15.7%Tralokinumab Dose 2 NCT02347176 · Phase 2 · registry result, not featured evidence 7.7%Tralokinumab Dose 3 NCT02347176 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —250mg Q2We NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 54 more results—Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250mg Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2% NCT04250337 · Phase 3 · combination 1.9% NCT05990725 · Phase 3 · registry result, not featured evidence —Q4W NCT04392154 · Phase 3 · registry result, not featured evidence —Q8W NCT04392154 · Phase 3 · registry result, not featured evidence 4.5%Q2W NCT04392154 · Phase 3 · registry result, not featured evidence 2.1%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 5.8%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —Lebrikizumab Pen NCT06444165 · Phase 3 · registry result, not featured evidence —Lebrikuzimab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 0.9%Double-blind Induction Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence · combination —Open-label Maintenance Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 1.6%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0%250mg Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —250 Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 2.4%250 mg NCT04626297 · Phase 3 · registry result, not featured evidence 2.4%250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT03443024 · Phase 2 · registry result, not featured evidence 5%250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence —125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence | 0.6%Tralokinumabf NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more results—Tralokinumab DB NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Tralokinumab OL NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT03131648 · Phase 3 —Q2W NCT03131648 · Phase 3 —Q4W NCT03131648 · Phase 3 —Q2W + optional TCS NCT03131648 · Phase 3 · combination —300 mg Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q4W NCT03160885 · Phase 3 —Q2W + Optional TCS NCT03160885 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —300 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 · combination —150 Q2W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —150 Q2W NCT03526861 · Phase 3 —150 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —300 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 · combination 4.3% NCT03587805 · Phase 3 · registry result, not featured evidence —Tralokinumab Subcutaneous Dosing b NCT05194540 · Phase 3 · registry result, not featured evidence —Tralokinumab+TCS Initial Treatment NCT05194540 · Phase 3 · registry result, not featured evidence · combination — NCT04587453 · Phase 3 · registry result, not featured evidence · combination —Safety Follow-up Period: Tralokinu NCT03761537 · Phase 3 · registry result, not featured evidence · combination —Treatment Period: Tralokinumab+TCS NCT03761537 · Phase 3 · registry result, not featured evidence · combination — NCT03562377 · Phase 2 · registry result, not featured evidence —Tralokinumab Dose 1 NCT02347176 · Phase 2 · registry result, not featured evidence —Tralokinumab Dose 2 NCT02347176 · Phase 2 · registry result, not featured evidence —Tralokinumab Dose 3 NCT02347176 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 2.1%250mg Q2We NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 54 more results3.8%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Escape Arm Week 24 to 48 - Mainten NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2%Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.7%250mg Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.9%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Escape Arm Week 24 to 48 - Mainten NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.4%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 22.2%Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.3% NCT04250337 · Phase 3 · combination 2.7% NCT05990725 · Phase 3 · registry result, not featured evidence 0%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence 0%Q8W NCT04392154 · Phase 3 · registry result, not featured evidence 4.4%Q2W NCT04392154 · Phase 3 · registry result, not featured evidence 3.5%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence 0%250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 0%250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence 1.8%250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 1.2%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05369403 · Phase 3 · registry result, not featured evidence 0%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence 2.4%250 mg Q2W then Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —Lebrikizumab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 0%Lebrikuzimab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 1.4%Double-blind Induction Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence · combination 5.7%Open-label Maintenance Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence 1.4%250 mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 1.8%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 4.8%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0.8%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0%250mg Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 12.5%250 Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0%Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 3.1%Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 2.6%Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 0.8%250 mg NCT04626297 · Phase 3 · registry result, not featured evidence —250 mg NCT04250350 · Phase 3 · registry result, not featured evidence 2.4%250 mg NCT04250350 · Phase 3 · registry result, not featured evidence 2.7%250 mg Q2W NCT03443024 · Phase 2 · registry result, not featured evidence 0%250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence 2.7%125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence | —Tralokinumabf NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more results1.9%Tralokinumab DB NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.9%Tralokinumab OL NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.8%Q2W NCT03131648 · Phase 3 1.5%Q2W NCT03131648 · Phase 3 3.9%Q4W NCT03131648 · Phase 3 4.8%Q2W + optional TCS NCT03131648 · Phase 3 · combination —300 mg Q2W NCT03160885 · Phase 3 1.7%Q2W NCT03160885 · Phase 3 0%Q2W NCT03160885 · Phase 3 3.4%Q4W NCT03160885 · Phase 3 2.9%Q2W + Optional TCS NCT03160885 · Phase 3 · combination 0%Q2W+TCS NCT03363854 · Phase 3 · combination 2.1%Q2W+TCS NCT03363854 · Phase 3 · combination 4.3%Q2W+TCS NCT03363854 · Phase 3 · combination 0%Q4W+TCS NCT03363854 · Phase 3 · combination 0.8%Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —300 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 · combination 3.1%150 Q2W NCT03526861 · Phase 3 1%300 Q2W NCT03526861 · Phase 3 0%150 Q2W NCT03526861 · Phase 3 0%150 Q4W NCT03526861 · Phase 3 0%300 Q2W NCT03526861 · Phase 3 0%300 Q4W NCT03526861 · Phase 3 3%300 Q2W NCT03526861 · Phase 3 · combination 9% NCT03587805 · Phase 3 · registry result, not featured evidence —Tralokinumab Subcutaneous Dosing b NCT05194540 · Phase 3 · registry result, not featured evidence 0%Tralokinumab+TCS Initial Treatment NCT05194540 · Phase 3 · registry result, not featured evidence · combination — NCT04587453 · Phase 3 · registry result, not featured evidence · combination 0%Safety Follow-up Period: Tralokinu NCT03761537 · Phase 3 · registry result, not featured evidence · combination 0.7%Treatment Period: Tralokinumab+TCS NCT03761537 · Phase 3 · registry result, not featured evidence · combination 2.8% NCT03562377 · Phase 2 · registry result, not featured evidence 6%Tralokinumab Dose 1 NCT02347176 · Phase 2 · registry result, not featured evidence 3.9%Tralokinumab Dose 2 NCT02347176 · Phase 2 · registry result, not featured evidence 0%Tralokinumab Dose 3 NCT02347176 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 250mg Q2We conjunctivitis 7.4% (placebo 2.8%) dermatitis atopic 5.7% (placebo 21.3%) nasopharyngitis 3.9% (placebo 2.8%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more resultsQ2W conjunctivitis 4.7% (placebo 2.8%) conjunctivitis allergic 4.7% (placebo 0.7%) asthma 3.8% (placebo 0.7%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W conjunctivitis 9.4% (placebo 2.8%) conjunctivitis allergic 6.3% (placebo 0.7%) dermatitis atopic 6.3% (placebo 21.3%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 bursitis 5.6% (placebo 0.7%) carpal tunnel syndrome 5.6% (placebo 0%) conjunctivitis 5.6% (placebo 2.8%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W covid-19 3.2% (placebo 2.1%) dermatitis atopic 3.2% (placebo 21.3%) hypertension 3.2% (placebo 0.7%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W covid-19 12.7% (placebo 2.1%) nasopharyngitis 9.5% (placebo 2.8%) dermatitis atopic 6.3% (placebo 21.3%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W abscess limb 10% (placebo 0%) chest wall abscess 10% (placebo 0%) nasopharyngitis 10% (placebo 2.8%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W covid-19 10% (placebo 2.1%) nasopharyngitis 10% (placebo 2.8%) oral herpes 10% (placebo 3.5%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 250mg Q2W dermatitis atopic 9.2% (placebo 25.5%) conjunctivitis 7.1% (placebo 2%) headache 5.1% (placebo 5.4%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W nasopharyngitis 8% (placebo 2%) dermatitis atopic 4.8% (placebo 25.5%) conjunctivitis 2.4% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W conjunctivitis allergic 11.1% (placebo 1.3%) covid-19 5.6% (placebo 1.3%) nasopharyngitis 5.6% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 asthma 18.2% (placebo 0%) dermatitis atopic 18.2% (placebo 25.5%) herpes dermatitis 9.1% (placebo 1.3%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W vaccination complication 6.8% (placebo 0%) dermatitis atopic 5.1% (placebo 25.5%) folliculitis 5.1% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W conjunctivitis 8.5% (placebo 2%) conjunctivitis allergic 6.8% (placebo 1.3%) covid-19 5.1% (placebo 1.3%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W hypercholesterolaemia 18.2% (placebo 0.7%) nasopharyngitis 18.2% (placebo 2%) acne 9.1% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W arthralgia 11.1% (placebo 0.7%) blood lactate dehydrogenase increased 11.1% (placebo 0%) blood uric acid increased 11.1% (placebo 0%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 conjunctivitis 4.6% (placebo 0%) headache 4.6% (placebo 1.3%) hypertension 2.6% (placebo 1.3%) NCT04250337 · Phase 3 · combination nasopharyngitis 25.4% conjunctivitis 17.7% dermatitis atopic 11.5% NCT05990725 · Phase 3 · registry result, not featured evidence Q4W nasopharyngitis 3.8% acne 1.9% attention deficit hyperactivity disorder 1.9% NCT04392154 · Phase 3 · registry result, not featured evidence Q8W accessory navicular syndrome 2% alanine aminotransferase increased 2% arthralgia 2% NCT04392154 · Phase 3 · registry result, not featured evidence Q2W covid-19 15.7% nasopharyngitis 11.4% dermatitis atopic 6.9% NCT04392154 · Phase 3 · registry result, not featured evidence Q4W covid-19 18.4% nasopharyngitis 9.2% dermatitis atopic 6.4% NCT04392154 · Phase 3 · registry result, not featured evidence 250 mg Q2W back pain 2.2% nasopharyngitis 2.2% acanthosis nigricans 1.1% NCT05372419 · Phase 3 · registry result, not featured evidence 250 mg Q2W back pain 4.8% blood creatine phosphokinase increased 4.8% dermatitis atopic 4.8% NCT05372419 · Phase 3 · registry result, not featured evidence 250 mg Q2W then 250 mg Q4W conjunctivitis 3.6% nasopharyngitis 3.6% acne 1.8% NCT05372419 · Phase 3 · registry result, not featured evidence 250 mg Q2W dermatitis atopic 5.8% upper respiratory tract infection 4.7% injection site pain 3.5% NCT05369403 · Phase 3 · registry result, not featured evidence 250 mg Q2W concussion 5.6% conjunctivitis 5.6% covid-19 5.6% NCT05369403 · Phase 3 · registry result, not featured evidence 250 mg Q2W then Q4W joint swelling 4.9% viral upper respiratory tract infection 4.9% acne 2.4% NCT05369403 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.7% (placebo 12.6%) conjunctivitis 11.4% (placebo 1.8%) conjunctivitis allergic 8.2% (placebo 2.7%) NCT05149313 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 24.5% (placebo 12.6%) conjunctivitis 11.8% (placebo 1.8%) conjunctivitis allergic 8.5% (placebo 2.7%) NCT05149313 · Phase 3 · registry result, not featured evidence 250 mg Q2W conjunctivitis allergic 18.3% (placebo 4.9%) covid-19 18.3% (placebo 2.4%) pyrexia 18.3% (placebo 15.9%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q2W covid-19 21.8% (placebo 2.4%) nasopharyngitis 12.7% (placebo 2.4%) acne 10.9% (placebo 6.1%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q2W covid-19 19% (placebo 2.4%) herpes simplex 19% (placebo 2.4%) nasopharyngitis 14.3% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q2W pyrexia 20.3% (placebo 15.9%) conjunctivitis allergic 17.1% (placebo 4.9%) conjunctivitis 9.8% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q4W pyrexia 18.5% (placebo 15.9%) conjunctivitis allergic 12.3% (placebo 4.9%) conjunctivitis 6.2% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence 250 Q2W covid-19 25% (placebo 2.4%) abdominal pain 12.5% (placebo 1.2%) acne 12.5% (placebo 6.1%) NCT04760314 · Phase 3 · registry result, not featured evidence Q4W covid-19 21.2% (placebo 2.4%) acne 18.2% (placebo 6.1%) headache 18.2% (placebo 11%) NCT04760314 · Phase 3 · registry result, not featured evidence Q2W pyrexia 34.4% (placebo 15.9%) conjunctivitis allergic 12.5% (placebo 4.9%) covid-19 12.5% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence Q4W covid-19 18.4% (placebo 2.4%) pyrexia 18.4% (placebo 15.9%) conjunctivitis allergic 13.2% (placebo 4.9%) NCT04760314 · Phase 3 · registry result, not featured evidence 250 mg covid-19 5.5% (placebo 3.9%) dermatitis atopic 4.7% (placebo 6.3%) headache 3.1% (placebo 0.8%) NCT04626297 · Phase 3 · registry result, not featured evidence 250 mg dermatitis atopic 12.6% nasopharyngitis 9.7% covid-19 9.2% NCT04250350 · Phase 3 · registry result, not featured evidence 250 mg Q2W nasopharyngitis 12% (placebo 3.8%) headache 5.3% (placebo 5.8%) injection site pain 5.3% (placebo 1.9%) NCT03443024 · Phase 2 · registry result, not featured evidence 250 mg Q4W upper respiratory tract infection 11.3% (placebo 5.8%) fatigue 5% (placebo 0%) diarrhoea 3.8% (placebo 0%) NCT03443024 · Phase 2 · registry result, not featured evidence 125 mg Q4W upper respiratory tract infection 8.2% (placebo 5.8%) nasopharyngitis 5.5% (placebo 3.8%) bacterial vaginosis 4.3% (placebo 0%) NCT03443024 · Phase 2 · registry result, not featured evidence | f nasopharyngitis 16.7% (placebo 7.6%) injection site reaction 6.4% (placebo 1.3%) dermatitis atopic 5.8% (placebo 5.1%) NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 29 more resultsinjection site reaction 7.9% (placebo 1.3%) nasopharyngitis 7.5% (placebo 7.6%) covid-19 0% (placebo 0%) NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W dermatitis atopic 25.2% (placebo 38.3%) viral upper respiratory tract infection 23.1% (placebo 20.9%) conjunctivitis 7.1% (placebo 2%) NCT03131648 · Phase 3 Q2W viral upper respiratory tract infection 20.6% (placebo 20.9%) dermatitis atopic 16.2% (placebo 38.3%) headache 8.8% (placebo 5.1%) NCT03131648 · Phase 3 Q4W viral upper respiratory tract infection 23.7% (placebo 20.9%) dermatitis atopic 18.4% (placebo 38.3%) bronchitis 9.2% (placebo 2%) NCT03131648 · Phase 3 Q2W + optional TCS viral upper respiratory tract infection 25.4% (placebo 20.9%) dermatitis atopic 21.8% (placebo 38.3%) conjunctivitis 7.3% (placebo 2%) NCT03131648 · Phase 3 · combination Q2W dermatitis atopic 16.4% (placebo 33.5%) upper respiratory tract infection 10% (placebo 8.5%) viral upper respiratory tract infection 8.3% (placebo 8.5%) NCT03160885 · Phase 3 Q2W upper respiratory tract infection 15.4% (placebo 8.5%) dermatitis atopic 14.3% (placebo 33.5%) viral upper respiratory tract infection 9.9% (placebo 8.5%) NCT03160885 · Phase 3 Q4W dermatitis atopic 15.7% (placebo 33.5%) upper respiratory tract infection 10.1% (placebo 8.5%) viral upper respiratory tract infection 6.7% (placebo 8.5%) NCT03160885 · Phase 3 Q2W + Optional TCS dermatitis atopic 20.4% (placebo 33.5%) upper respiratory tract infection 11.6% (placebo 8.5%) viral upper respiratory tract infection 10.4% (placebo 8.5%) NCT03160885 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 19% (placebo 17.1%) dermatitis atopic 7.6% (placebo 4.9%) conjunctivitis 3.8% (placebo 2.4%) NCT03363854 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 21.1% (placebo 17.1%) dermatitis atopic 8.4% (placebo 4.9%) headache 7.4% (placebo 2.4%) NCT03363854 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 17.4% (placebo 17.1%) upper respiratory tract infection 10.1% (placebo 4.9%) injection site reaction 7.2% (placebo 0%) NCT03363854 · Phase 3 · combination Q4W+TCS viral upper respiratory tract infection 13% (placebo 17.1%) headache 7.2% (placebo 2.4%) injection site reaction 5.8% (placebo 0%) NCT03363854 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 19.4% (placebo 17.1%) conjunctivitis 11.1% (placebo 2.4%) headache 8.7% (placebo 2.4%) NCT03363854 · Phase 3 · combination 150 Q2W viral upper respiratory tract infection 19.4% (placebo 8.5%) dermatitis atopic 12.2% (placebo 11.7%) upper respiratory tract infection 8.2% (placebo 4.3%) NCT03526861 · Phase 3 300 Q2W viral upper respiratory tract infection 12.4% (placebo 8.5%) upper respiratory tract infection 11.3% (placebo 4.3%) dermatitis atopic 7.2% (placebo 11.7%) NCT03526861 · Phase 3 150 Q2W pharyngitis 25% (placebo 4.3%) acne 8.3% (placebo 4.3%) acute sinusitis 8.3% (placebo 1.1%) NCT03526861 · Phase 3 150 Q4W dermatitis atopic 14.3% (placebo 11.7%) acne 7.1% (placebo 4.3%) attention deficit/hyperactivity disorder 7.1% (placebo 0%) NCT03526861 · Phase 3 300 Q2W influenza 18.2% (placebo 1.1%) upper respiratory tract infection 18.2% (placebo 4.3%) viral upper respiratory tract infection 18.2% (placebo 8.5%) NCT03526861 · Phase 3 300 Q4W bacterial vaginosis 7.7% (placebo 0%) conjunctivitis 7.7% (placebo 0%) inappropriate schedule of drug administration 7.7% (placebo 0%) NCT03526861 · Phase 3 300 Q2W viral upper respiratory tract infection 18.8% (placebo 8.5%) upper respiratory tract infection 10.7% (placebo 4.3%) dermatitis atopic 8.1% (placebo 11.7%) NCT03526861 · Phase 3 · combination nasopharyngitis 22.2% atopic dermatitis 21% covid-19 17.6% NCT03587805 · Phase 3 · registry result, not featured evidence injection site reaction 5.9% dermatitis atopic 4.4% conjunctivitis 2.9% NCT05194540 · Phase 3 · registry result, not featured evidence · combination viral upper respiratory tract infection 2.7% (placebo 1.2%) arthralgia 1.3% (placebo 0%) cholelithiasis 1.3% (placebo 0%) NCT03761537 · Phase 3 · registry result, not featured evidence · combination viral upper respiratory tract infection 26.8% (placebo 1.2%) headache 15.2% (placebo 0%) upper respiratory tract infection 7.2% (placebo 0%) NCT03761537 · Phase 3 · registry result, not featured evidence · combination dermatitis atopic 11.2% (placebo 12.1%) viral upper respiratory tract infection 9.3% (placebo 2.8%) headache 2.8% (placebo 1.9%) NCT03562377 · Phase 2 · registry result, not featured evidence nasopharyngitis 22% (placebo 11.8%) upper respiratory tract infection 10% (placebo 9.8%) dermatitis atopic 6% (placebo 7.8%) NCT02347176 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 11.8%) upper respiratory tract infection 11.8% (placebo 9.8%) headache 7.8% (placebo 3.9%) NCT02347176 · Phase 2 · registry result, not featured evidence nasopharyngitis 25% (placebo 11.8%) headache 7.7% (placebo 3.9%) upper respiratory tract infection 7.7% (placebo 9.8%) NCT02347176 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 2 versus Phase 3.
- ePopulation comparability has not been reviewed for 35 of these studies.
- fPopulation comparability has not been reviewed for 41 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
lebrikizumab
show 5 more results
show 15 more results
show 5 more results
show 3 more results
show 5 more results
show 3 more results
show 4 more results
show 15 more results
show 1 more result
show 3 more results
+ 74 further endpoints in the CSV export.
tralokinumab
+ 32 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lebrikizumab's landscape · tralokinumab's landscape